newsfilter
← Latest News
GlobeNewswire·

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

RMD
  • ResMed reported Q4 fiscal 2026 revenue of $1.5 billion, a 9% increase year-over-year (8% on a constant currency basis).
  • Q4 GAAP diluted earnings per share rose 2% to $2.64, while non-GAAP diluted earnings per share increased 16% to $2.95.
  • Full-year 2026 revenue grew 10% to $5.7 billion (8% on a constant currency basis) with non-GAAP diluted earnings per share up 17% to $11.17.
  • The company returned $1.0 billion to shareholders in FY2026 through share repurchases and dividends, an increase of over 70% compared to the prior year.
  • ResMed guided to return more than $1.85 billion to shareholders in FY2027 via share repurchases and dividends, including a 10% quarterly dividend increase to $0.66.
  • FY2026 operating cash flow totaled $1.8 billion, generating $1.6 billion in free cash flow to fund innovation, market leadership, and shareholder returns.
  • ResMed announced an agreement to sell its MatrixCare business, with the transaction expected to close in Q1 of fiscal 2027.
  • The company completed the acquisition of Noctrix Health, a developer of FDA De Novo classified wearable therapeutics for Restless Leg Syndrome.
  • New product launches included AirSense 11 in Taiwan, AirCurve 11 ST/ST-A in the U.S., AirTouch F30i Comfort in Brazil and Chile, and a partnership with ŌURA for sleep health education.
  • GAAP gross margin for FY2026 was 61.1%, an expansion of 170 basis points, while non-GAAP gross margin reached 62.4%, up 240 basis points.
  • The company recorded $41.9 million in Astral field safety notification expenses during the fourth quarter, impacting GAAP gross margin but excluded from non-GAAP metrics.